Niraparib OverviewNiraparib (trade name Zejula) is an orally active small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer. Niraparib was granted fast track designation by the US Food and Drug Administration (FDA), and Tesaro submitted a new drug application in 2016. It was approved on 27 March 2017 in the US, and has been approved in Europe on 16 November 2017. Contents 1 Medical uses 2 Contraindications 3 Side ef...
Read more Niraparib Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Niraparib
Recent Niraparib Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Capsule: 100mg